Tags : Lymphoma

$Roche’s Polivy (polatuzumab vedotin-piiq) Combination Therapy Receives FDA’s Accelerated Approval for Relapsed/Refractory Lymphoma$

Regulatory

Roche’s Polivy (polatuzumab vedotin-piiq) Combination Therapy Receives FDA’s Accelerated Approval

Tuba Khan June 11, 2019

Shots: The accelerated approval is based on P-Ib/II GO29365 study results involves assessing of Polivy + bendamustine + Rituxan (BR)/Gazyva (obinutuzumab) vs BR in patients with r/r follicular lymphoma or DLBCL with 2L+ treatment The P-Ib/II GO29365 study results: CRR (40% vs 18%); objective response (45% vs 18%); DOR lasting at least 6mos. (64% vs […]Read More

$Kite Reports Results of Yescarta (axicabtagene ciloleucel) in ZUMA-1 trial for Refractory Large B-Cell, Lymphoma, Presented at ASH 2018$

Biotech

Kite Reports Results of Yescarta (axicabtagene ciloleucel) in ZUMA-1 trial

Vartika Singh December 4, 2018

Shots: The ZUMA-1 trial involves assessing of Yescarta in patients with refractory large B-cell lymphoma for a duration of two years ZUMA-1 trial results (N=101): OR 83%; CR 58%; median follow up @27.1, 24 mos. (39%, 93% remain in response); mDOR 11.1 mos.; with no new safety signals observed Yescarta (axicabtagene ciloleucel) is novel CAR […]Read More

Claritas Collaborates with CMAX to Initiate P-I Study of R-107 for Pulmonary Arterial Hypertension

Vertex Amend its Collaboration with CRISPR Therapeutics for Development and Commercialization of CTX001 in SCD and Beta Thalassemia

Spark Therapeutics Signs an Option Agreement with Senti Bio to Develop Precision Gene Therapies

BMS and PsiOxus Therapeutics Expand their 2016 Immuno-Oncology Collaboration

Prestige Biopharma and Pharmapark Sign an Exclusive License and Supply Agreement to Commercialize HD204 (biosimilar, bevacizumab) in Russia

PlantForm Signs Research and Development Agreement with Bio-Manguinhos/Fiocruz to Develop Biosimilar Pembrolizumab

Johnson & Johnson Publishes Results of COVID-19 Single Shot Vaccine in NEJM

J&J Pauses Dosing of COVID-19 Vaccine Due to Blood Clotting

LEXEO Therapeutics Receives the US FDA’s Fast Track Designation for LX1001 to Treat APOE4 Associated Alzheimer Disease

GW Pharmaceuticals’ Epidyolex (cannabidiol) Receives EC’s Approval for the Treatment of Seizures Associated with Tuberous Sclerosis Complex

AgeneBio Reports Completion of Patient Enrollment in P-IIB HOPE4MCI Trial for AGB101 to Treat Amnestic Mild Cognitive Impairment due to Alzheimer Disease

TG Therapeutics Initiates Patient Enrolment in P-III ULTRA-V Trial for Triple Combination Regimen to Treat R/R Chronic Lymphocytic Leukemia

Tags : Lymphoma

Roche’s Polivy (polatuzumab vedotin-piiq) Combination Therapy Receives FDA’s Accelerated Approval

Kite Reports Results of Yescarta (axicabtagene ciloleucel) in ZUMA-1 trial

Latest Posts

PharmaShots’ Key Highlights of First Quarter 2021

Claritas Collaborates with CMAX to Initiate P-I Study of R-107 for Pulmonary Arterial Hypertension

Johnson & Johnson Publishes Results of COVID-19 Single Shot Vaccine in NEJM

AgeneBio Reports Completion of Patient Enrollment in P-IIB HOPE4MCI Trial for AGB101 to Treat Amnestic Mild Cognitive Impairment due to Alzheimer Disease

Tags : Lymphoma

Latest Posts

Categories

Related Topics